Sunshine Act

Medicare numbers trigger physician anger

Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.

Sunshine data highlights major billers

Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.

Glaxo onboards promotional doctors

The drugmaker revealed part 2 of its plan not to pay doctors to speak on GSK's behalf: it will make them employees.

Companies view Sunshine differently

Companies view Sunshine differently

By

A report indicates pharma companies do not agree on what research needs to be reported.

House members oppose CMS stance on reprints

Their letter to CMS voices disagreement with the decision to make textbooks and journals reportable under the Sunshine Act.

Many unclear on 2013 Sunshine data

Many unclear on 2013 Sunshine data

By

A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.

Good day, Sunshine: Tools help docs track payments

Good day, Sunshine: Tools help docs track payments

By

With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.

Industry pushing for further clarity on Sunshine Act

Industry pushing for further clarity on Sunshine Act

By

With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.

Business briefs: Reps mum on adverse events; FCC's new mHealth director; med schools tighten speaking limits

A study finds sales reps find time to talk benefits, but not risks, even when touting black-box drugs; FCC has named its new mHealth director; pharma scaled back its food budgets last year; and AMSA says 18 med schools now ban faculty from speakers bureau participation

Business briefs: BMS, Sanofi, UK Sunshine

BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.

Business briefs: AstraZeneca, Everyday Health, J&J

AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales

Gift study shows med students still being comped

By

Gift bans or no, students still connect with drug companies, a study has found.

Sunshine spawns fresh questions for med ed

By

New transparency rules set to lay bare financial ties between physicians and pharma will be a mixed bag for medical education, providers say.

CMS warms to some stakeholders, burns others with Sunshine rule

By

Clinical Research Organizations, marketing research firms, accredited CME providers and lawyers look to be the big winners in CMS's Sunshine Act rule.

Researchers find schools minting pitch-resistant docs

By

A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.

CMS releases "Sunshine" final rule: federal preemption, August start date

CMS releases "Sunshine" final rule: federal preemption, August start date

By

CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.

Business briefs: Abbott, Sunshine, Allergan and Watson

Abbott releases its 2012 numbers, Sen. Grassley demands Sunshine Act action from CMS and Allergan and Watson flex their purchasing power.

Company news: Edelman, CMS, McKesson

Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.

GSK's Connelly: We've changed our ways (and please don't imprison execs)

GSK's Connelly: We've changed our ways (and please don't imprison execs)

By

GlaxoSmithKline's Dierdre Connelly peeled back the curtain on the company's sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.

For Bay State, "modest meals" are in the eye of the beholder

For Bay State, "modest meals" are in the eye of the beholder

By

As the Massachusetts Department of Public Health deliberates the exact shape of a rule change allowing industry-sponsored meals for physicians in speaker programs, pharma foes and industry advocates are squaring off over the definition of "modest meals and refreshments."

Sunshine Act could scare docs away from commercially-supported CME

Sunshine Act could scare docs away from commercially-supported CME

By

Physicians are reconsidering their participation in industry-sponsored CME, fearful that their inclusion in Sunshine Act databases as having received payments from companies will tarnish their reputations and fuel perceptions of conflicts of interest, a survey has found.

Massachusetts gift ban under attack (again)

Massachusetts gift ban under attack (again)

By

Massachusetts legislators aren't just sick of the Prescriptions Drug Gift Ban -- they're looking to wipe it from the books.

PhRMA conferees fault industry for poor messaging

PhRMA conferees fault industry for poor messaging

By

PhRMA's annual meeting in Boston was full of talk about how scientific advances are pushing the boundaries of medicine's potential, but the mood was woe-is-me as members pondered their industry's poor public reputation.

Journal "pharmascolds" skew policy, says study

By

Medical journal coverage of the question of physician-industry relationships is "unbalanced" and may be skewing public policy towards ever-more restrictive safeguards against industry influence.

Study says docs favor COI disclosure

Study says docs favor COI disclosure

By

About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest to patients.

Market research kept out of Sunshine law

Market research kept out of Sunshine law

By

The Physician Payment Sunshine Act maintains the exclusion for marketing research incentives

Require disclosure of pharma ties, most docs say

Require disclosure of pharma ties, most docs say

By

The majority of physicians agrees that it's important to disclose to patients any financial relationships with drug and device companies but, research shows, there remains considerable rearguard sentiment to transparency.

Grassley blasts CMS foot-dragging on Sunshine Act

Grassley blasts CMS foot-dragging on Sunshine Act

By

The Centers for Medicare and Medicaid Services, now a month overdue to issue draft guidelines for reporting pharma-physician contacts as required under healthcare reform legislation, said the department is working on it, but offered nothing in the way of a timeline.

Lilly becomes latest pharma to disclose non-cash transfers

Lilly becomes latest pharma to disclose non-cash transfers

By

Eli Lilly reported paying $48.1 million to 45,440 physicians and/or 1,827 healthcare organizations during the first quarter, most of it for research and educational programs.

In protecting market research, federal exclusion may not always apply

In protecting market research, federal exclusion may not always apply

By

Thanks to the work of lobbyists, marketing research-related payments are explicitly excluded from Sunshine legislation enacted Tuesday as part of the healthcare overhaul. But the exclusion may not always apply.

Email Newsletters